For Oncology Professionals
OncoDNA solutions solve problems faced by Oncologists by identifying the most relevant treaments and clinical trials
Our aim is to help you better understand and use Comprehensive Genomic Profiling* (CGP) for patients with solid tumours providing full support from test selection to making use of the results.
- Thousands of oncologists using our tests across the globe
- 10+ years of experience in CGP design and testing
- Daily curated database signposting oncologists to clinical trials and newly available drugs
Clinical solutions designed by clinical oncology experts
Comprehensive pan-cancer biomarker test for solid biopsies based on NGS DNA, RNA, and protein analysis.
- 638 DNA, 22 RNA
- HRD, MSI, TMB, LOH
- Tunr Around Time <2 weeks
- 70 genes
- SNVs, Indels
- Gene translocations, unusual splicing
- TERT promoter
Clinical actionable reporting
Molecular profiling data simply presented signposting the oncologist to actions that can compliment and improve patient treatment plans
OncoSHARE (Powered by OncoKDM®)
Integration of all data into one comprehensive report with an
easy-to-read summary supplemented with detailed scientific data if required.
Treatment recommendations are based on the latest scientific and clinical publications (evidenced by the bibilography).
Analysis details and quality control
Accurate and reliable clinical interpretation of genomic data is essential for labs. OncoKDM provides the necessary views to labs to ensure the quality of sequencing data by enabling them to control key values. However, if labs require a deeper insight into molecular data such as hotspots, they can utilize the advanced Mercury platform.
Watch the videoVariants detection
Our comprehensive variant analysis allows labs to discover all relevant variants detected through sequencing, which are categorized as SNV, INDEL, CNV, AMP. Additionally, we classify each variant based on its biological and therapeutic impact, using the TIER classification system that follows the established ACMG/AMP guidelines ensuring labs receive detailed and accurate information about each variant's potential clinical significance.
Watch the videoGenomic signatures
In addition to identifying individual alterations, the OncoDEEP kit also focuses on complex genomic signatures and rearrangements, such as HRD, MSI, and TM. Our process includes scoring and reporting the expression of these signatures into OncoKDM, enabling labs to access a comprehensive overview of their patients' molecular profile. By incorporating these signatures into the analysis, we provide a more complete picture of the tumor's biology ensuring the best clinical interpretation.
Watch the videoDrugs recommendation
OncoKDM treatment recommendation provides a clear overview of the most effective treatment options based on official guidelines and clinical evidence, ensuring that non-responders are spared from unnecessary toxicities and ineffective therapies. We list each drug with its associated biomarkers and approval details, allowing oncologists to make informed decisions about the best treatment for the patients.
Watch the videoClinical Trials
Easily find worldwide, relevant clinical trials that have reached at least Phase 2, based on your patient's specific condition and molecular profile. With our advanced search capabilities, you can quickly identify clinical trials that are most likely to benefit your patients and provide them with the latest treatment options available.
Watch the videoA comprehensive summary
Our comprehensive reporting includes key findings, simplified pathway analysis, and treatment recommendations based on both molecular and clinical evidence. This allows labs to easily understand the implications of the molecular profiling results and make informed decisions about the best course of treatment for the patients.
Watch the video
Testing step by step
Our teams are at hand to assist you every step of the way – from discussing the relevance of the test for your patient and easing the sample collection to understanding the clinical recommendations listed in the report.
FAQ
How to order an analysis?
How do I order a test?
Select your sample type and order the relevant molecular profiling kit by following these steps.
In the ‘Orders’ tab click on the ‘Order analysis’ button to launch the order wizard
1) Enter or search for your patient reference (name or ID) to associate the sample to your patient.
Tips: You can avoid this step by launching the order wizard directly through your patient case page.
2) Depending on whether you already have a kit or not you can enter the kit barcode or select a product. (available products might differ among sales agreement).
3) Choose or enter the shipping address
4) Complete the clinical form. Note that the analysis won’t be launched until OncoDNA gets the Patient Informed Consent form back. You can download the PICF by using clicking on the link at the top of the clinical form.
5) Once the Clinical Form completed you can choose your payment method:
After the payment process, the system will display the order summary (downloadable)
What is OncoSHARE?
The link between patients, oncologists and OncoDNA.
Consult the report, network and benchmark with oncologists from all over the world!
OncoSHARE is the OncoDNA interactive web interface, accessible to oncologists and patients, for reporting results, matching similar clinical cases, sharing experience on drug efficacy, and finding out which drug can be applied.
OncoSHARE allows oncologists and patients to connect with each other and encourages the sharing of genomic and treatment data, creating a network effect.
If you need any further information, please contact support@oncodna.com
Is reimbursement available for these tests?
Major health insurers, including BUPA Global Insurance, have approved reimbursement in the United Kingdom for our most comprehensive theranostic solution, OncoSTRAT&GO.
BUPA Global Insurance has a specific code (7331B) for the reimbursement of our test.
A direct contract is in place between the two companies, so neither the oncologist nor the patient needs to pay for taking advantage of the benefits of cancer precision medicine.
For all other major UK insurance companies, there is a generic code, BC001211. Oncologists can reference this code to any insurer when requesting the test and when the insurer authorises it for a patient, it can then be reimbursed.
Insurance companies in other countries, like Spain, Chile, South Africa or Poland, are also covering totally or partially the cost of our tests.
Patients can also pay out of pocket please contact us directly for pricing and a secure link for processing payment.
If you need any further information, please contact support@oncodna.com
